Health, Wellness & Beauty

SHERIDAN, WYOMING – November 10, 2024 – Cardinal Health (NYSE: CAH) today reported strong first quarter fiscal year 2025 results, with non-GAAP operating earnings increasing 12% to $625 million and non-GAAP diluted EPS increasing 9% to $1.88. The company also raised its fiscal year 2025 non-GAAP EPS guidance to $7.75 to $7.90, from $7.55 to $7.70.“We began fiscal 2025 by delivering strong operational and financial performance, led by the Pharmaceutical and Specialty Solutions segment,” said Jason Hollar, CEO of Cardinal Health. “The strength and resiliency of our largest and most significant business continues to shine, giving us confidence to raise our fiscal 2025 enterprise guidance only a quarter into the year. Across the business, we remain focused on executing our plan to best serve our customers and create value for our shareholders.”

SHERIDAN, WYOMING – November 10, 2024 – Cardinal Health (NYSE: CAH) today announced the grand opening of its new distribution center in Boylston, Massachusetts, supporting its U.S. Medical Products and Distribution business. The facility provides healthcare customers in Massachusetts, New Hampshire, Rhode Island, Maine, Vermont, and Eastern Connecticut with modernized operations and expanded capacity, as well as specialized handling capabilities for products with strict storage requirements, available early 2025. At nearly 317,000 square feet, the new facility has replaced the Cardinal Health Bedford, Massachusetts, distribution center with double the warehouse space and triple the capacity for product storage locations.

SHERIDAN, WYOMING – November 10, 2024 – SHERIDAN, WYOMING – November 10, 2024 – Heart attacks and cardiac arrests are serious heart-related emergencies that can be life-threatening. While the terms are often used interchangeably, they are distinct conditions with different causes and treatments.

Heart Attack: A 'Plumbing' Problem

A heart attack occurs when blood flow to the heart is severely restricted or completely blocked. This blockage, typically caused by plaque buildup in the coronary arteries, deprives the heart muscle of oxygen, leading to tissue damage.

"A heart attack is often referred to as a 'plumbing' problem, because blood flow to the heart is interrupted, causing heart tissue to die," explains Rachel Keever, M.D., Medical Executive, Health Systems Integration at Johnson & Johnson Innovative Medicine's Cardiovascular therapeutic area in the U.S.

Risk Factors for Heart Attack

SHERIDAN, WYOMING – November 10, 2024 – SHERIDAN, WYOMING – November 10, 2024 – Shockwave Medical, a Johnson & Johnson MedTech company and a global leader in circulatory restoration, announced positive 30-day results from its DISRUPT BTK II study. This post-market study evaluated the safety and effectiveness of the Shockwave Peripheral IVL System in treating calcified peripheral lesions below the knee (BTK), including patients with critical limb-threatening ischemia (CLTI).

Addressing Peripheral Artery Disease with IVL Technology

Peripheral artery disease (PAD) affects over 8 million people aged 40 and older in the United States. PAD can significantly impact quality of life and increase the risk of heart attack or stroke. CLTI, the most severe form of PAD, affects nearly 2 million U.S. patients and carries a high risk of amputation and mortality.

SHERIDAN, WYOMING – November 10, 2024 – Johnson & Johnson MedTech, a global pioneer in orthopedic technologies, has showcased its advanced portfolio of products and data-driven solutions at the American Association of Hip and Knee Surgeons (AAHKS) 2024 Annual Meeting in Dallas. The company's latest innovations are set to redefine joint reconstruction procedures, enhancing surgical accuracy and patient outcomes.
Aldo Denti, Company Group Chairman, Orthopaedics, Johnson & Johnson MedTech, expressed his enthusiasm for the company's recent achievements, stating, “2024 has been a remarkable year of progress for Johnson & Johnson MedTech, marked by numerous clearances, launches, and strategic collaborations. Most notably, this was the single most successful year for major launches for the VELYS™ Enabling Tech portfolio.”   
Solutions in Motion: A Holistic Approach to Joint Reconstruction

SHERIDAN, WYOMING – November 10, 2024 – Johnson & Johnson is at the forefront of a healthcare revolution, harnessing the power of artificial intelligence (AI) to transform patient care. From enhancing surgical procedures and accelerating drug discovery to personalizing treatments and optimizing the supply chain, AI is integral to Johnson & Johnson's mission to improve the lives of people worldwide.

AI's role in healthcare has evolved significantly since its early conceptualization in the 1950s. While initial limitations hindered its widespread adoption, recent advancements have led to a surge of AI-powered medical devices and applications. "In the next few years, AI is going to play an even bigger role," says Jim Swanson, Executive Vice President and Chief Information Officer at Johnson & Johnson.

Revolutionizing Surgical Procedures

SHERIDAN, WYOMING – November 9, 2024 – AGFA HealthCare, a leading provider of medical imaging solutions, today announced that Groupe santé CHC in Liege, Belgium, has selected the AGFA HealthCare Enterprise Imaging Platform for its entire medical imaging department. The 10-year contract includes supplying, installing, commissioning, and maintaining Enterprise Imaging for Radiology and the Enterprise Imaging VNA. The platform will be used for hospital imaging across various clinic and polyclinic sites, with the entire department performing over 400,000 examinations annually.

Enhancing Efficiency for Better Patient Care

The Enterprise Imaging Platform will deliver high performance and efficiency, enabling Groupe santé CHC's radiologists to perform examinations under optimal conditions.

Dr. François Dister, head of Groupe santé CHC’s medical imaging department, emphasizes the importance of staying at the forefront of medical technology:

SHERIDAN, WYOMING – November 9, 2024 – AGFA HealthCare, a leading provider of diagnostic imaging and healthcare IT solutions, joins the global healthcare community in celebrating International Day of Radiology (IDoR) on November 8th. This annual event commemorates the groundbreaking discovery of X-rays by Wilhelm Röntgen in 1895, a pivotal moment that revolutionized medical diagnosis and treatment.

IDoR serves as a tribute to the invaluable contributions of radiologists, radiographers, and other imaging professionals who play a critical role in patient care. Their expertise and dedication enable the early detection, diagnosis, and management of a wide range of medical conditions, ultimately improving patient outcomes.

SHERIDAN, WYOMING – November 9, 2024 – AGFA HealthCare, a leading provider of enterprise imaging solutions, today announced the successful implementation of its XERO® Exchange Network (XEN) across five NHS Trusts in South Yorkshire and Bassetlaw, UK. This deployment marks a significant milestone in regional healthcare collaboration, enabling seamless image sharing between hospitals, regardless of their existing Picture Archiving and Communication System (PACS) or Radiology Information System (RIS).

The XERO® Exchange Network (XEN) is a groundbreaking solution that facilitates real-time federation across different healthcare organizations. By connecting disparate systems, XEN empowers clinicians with instant access to a patient's complete imaging history, breaking down traditional barriers and streamlining workflows.

SHERIDAN, WYOMING – November 9, 2024 – Shockwave Medical, a Johnson & Johnson MedTech company, has announced encouraging results from its DISRUPT BTK II study, which investigated the use of Intravascular Lithotripsy (IVL) in patients with calcified peripheral lesions below the knee. The study focused on patients with Critical Limb-Threatening Ischemia (CLTI), a severe form of peripheral artery disease (PAD) that can lead to amputation.

PAD affects over 8 million people over 40 in the United States, with CLTI representing the most serious form. It can lead to a 40% major amputation rate within a year and a 50% mortality rate within five years.
The DISRUPT BTK II study enrolled 250 patients with 305 lesions across 38 sites worldwide. The study population included a high percentage of patients with comorbidities such as diabetes, chronic total occlusions (CTOs), and moderate-to-severe calcium, making them particularly challenging to treat.